Skip to main content
Clinical Trials/NCT05028894
NCT05028894
Completed
Not Applicable

23andMe Idiopathic Pulmonary Fibrosis Research Study

23andMe, Inc.1 site in 1 country690 target enrollmentJune 5, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Pulmonary Fibrosis
Sponsor
23andMe, Inc.
Enrollment
690
Locations
1
Primary Endpoint
IPF Symptom Progression 6 month follow-up
Status
Completed
Last Updated
last year

Overview

Brief Summary

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Detailed Description

This study will recruit 1,000 people who have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS). Eligible participants who consent to participate in 23andMe Research and the IPF Research Study will receive a 23andMe Health + Ancestry kit at no cost. Participants will provide a saliva sample and take a baseline survey online answering questions about their disease diagnosis, testing, treatment, and symptoms. Participants will also be asked to take the same survey 3, 6, and 9 months after completing the baseline survey. The data collected from this study will be incorporated into the 23andMe Database and used to better understand the underlying genetic and environmental factors that contribute to IPF.

Registry
clinicaltrials.gov
Start Date
June 5, 2020
End Date
May 5, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS)
  • Are 18+ years old
  • Live in the US

Exclusion Criteria

  • Have been diagnosed with sarcoidosis or hypersensitivity pneumonitis

Outcomes

Primary Outcomes

IPF Symptom Progression 6 month follow-up

Time Frame: 6 months post baseline

Survey asking about disease diagnosis, testing, treatments, and symptom progression

IPF Symptom Progression 9 month follow-up

Time Frame: 9 months post baseline

Survey asking about disease diagnosis, testing, treatments, and symptom progression

IPF Symptom Progression 3 month follow-up

Time Frame: 3 months post baseline

IPF Symptom Progression 3 month follow-up

IPF Symptom Progression Baseline

Time Frame: Baseline

Survey asking about disease diagnosis, testing, treatments, and symptom progression

Study Sites (1)

Loading locations...

Similar Trials